Immunic (IMUX) Depreciation & Amortization (CF) (2013 - 2026)

Immunic has disclosed Depreciation & Amortization (CF) across 14 years of filings, most recently posting $33000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $33000.0, down 23.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $158000.0 (up 4.64% YoY), and the FY2025 annual result was $168000.0, up 25.37% from the prior year.
• Depreciation & Amortization (CF) came in at $33000.0 for Q1 2026 at Immunic, down from $42000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $43000.0 in Q1 2025 to a low of $17000.0 in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $32000.0 (2023), against an average of $30764.7.
• Across the five-year window, Depreciation & Amortization (CF) sank 52.5% in 2022 and surged 100.0% in 2023, its largest moves.
• Immunic's Depreciation & Amortization (CF) stood at $19000.0 in 2022, then advanced by 21.05% to $23000.0 in 2023, then soared by 52.17% to $35000.0 in 2024, then grew by 20.0% to $42000.0 in 2025, then retreated by 21.43% to $33000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $33000.0 (Q1 2026), $42000.0 (Q4 2025), and $40000.0 (Q3 2025), per Business Quant data.